Akebia Therapeutics (AKBA) has disclosed a new risk, in the Regulation category.
Akebia Therapeutics faces significant business risks if it fails to obtain or maintain marketing approvals for its product candidates in jurisdictions outside the United States. The regulatory approval process varies across countries and can involve additional testing and substantial time differences compared to FDA processes. Brexit adds complexity, as the UK now requires separate approvals, with the effectiveness of the new International Recognition Procedure still uncertain. Furthermore, potential changes in EU pharmaceutical regulations could impact the company’s long-term business prospects.
The average AKBA stock price target is $8.75, implying 417.75% upside potential.
To learn more about Akebia Therapeutics’ risk factors, click here.